VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced the Company's Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Ne...
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Dr. Giovanni Selvaggi, who has brought several oncology drugs to market, joins CEL-SCI as Clinical Advisor....
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2024 financial results....
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer....
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI appoints Mario Gobbo to its Board of Directors....
NEW YORK--(BUSINESS WIRE)--Channel V Media (CVM), a communications strategy and PR firm that builds market momentum for both established enterprises and emerging venture‑backed innovators, today ann...
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI's LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology....
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation issues letter to shareholders....
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $7.75 million public offering of common stock....
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces pricing of $7.75 million public offering of common stock....
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--European Medicines Agency grants CEL-SCI a waiver of strict pediatric requirements, clearing the path towards marketing authorization for Multikine....